Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects

Next Previous
Trial Profile

An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satricabtagene autoleucel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 18 Mar 2025 According to a CARsgen media release, data from this study published in Journal of Clinical Oncology and the Journal for ImmunoTherapy of Cancer.
  • 04 Jun 2024 Final Results of safety profile and efficacy , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jun 2024 According to a CARsgen media release, data from the study were published in the prestigious journal Nature Medicine and presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting on June 3, 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top